Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy

(2015) Eisuke Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of HIV-1 Resistance to Tenofovir AlafenamideIn Vitro

(2015) Nicolas A. Margot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroVirology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate

(2015) Christian Callebaut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

(2014) Paul E. Sax et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

(2014) M. Markowitz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping

(2014) Wan-Ping Lee et al.   PLoS One

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients

(2014) Kirsten White et al.   Viruses-Basel

Single-tablet regimens in HIV: does it really make a difference?

(2013) Isabel Aldir et al.   CURRENT MEDICAL RESEARCH AND OPINION

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Increasing Rate of TAMs and Etravirine Resistance in HIV-1–Infected Adults Between 12 and 24 Months of Treatment

(2013) Eugène Messou et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Increase in Single-Tablet Regimen Use and Associated Improvements in Adherence-Related Outcomes in HIV-Infected Women

(2013) David B. Hanna et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

De novo assembly of highly diverse viral populations

(2012) Xiao Yang et al.   BMC GENOMICS

Transmitted Drug-Resistant HIV Type 1 Remains Prevalent and Impacts Virologic Outcomes Despite Genotype-Guided Antiretroviral Therapy

(2011) Toshibumi Taniguchi et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transporters

(2011) James J Kohler et al.   LABORATORY INVESTIGATION

HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir

(2010) Vici Varghese et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®)

(2010) Emma D. Deeks et al.   DRUGS

Renal toxicity associated with tenofovir use

(2010) Sonia Rodriguez-Nóvoa et al.   Expert Opinion On Drug Safety

Cathepsin A is expressed in primary human antigen-presenting cells

(2009) Michael Reich et al.   IMMUNOLOGY LETTERS

Unknown

(2008)   CLINICAL INFECTIOUS DISEASES

Unknown

(2008) G. Birkus et al.   MOLECULAR PHARMACOLOGY